TCOYD Home
Watch and receive credit for
the Advancing Insulin Therapy lectures.
 
 
 
image

A CME Dinner Program Series


Advancing Insulin Therapy:

Timely Initiation, Basal Insulin Titration, and Postprandial Glucose Control

The importance of postprandial glucose control has long been overlooked. In type 2 diabetes, there is an unmet need for ultra fast-acting insulins to more effectively and efficiently control post-meal glucose values while simultaneously limiting delayed hypoglycemia and weight gain. In addition to controlling postprandial glucose values, there is a need to treat incidental hyperglycemia between meals when appropriate, which points to the demand for a rapid-on, rapid-off insulin. Identification of postprandial elevation is an important first step, followed by the design of an individualized insulin regimen to address basal and prandial insulin needs, which is crucial for overall safe and effective glucose control.

There is a marked behavioral resistance to advancing insulin therapy in type 2 diabetes for not only patients, but also HCPs. In particular, HCPs avoid intensifying mealtime insulin for a host of reasons: time constraints, or the perception of time constraints, lack of comfort and confidence regarding how to intensify and titrate mealtime therapy, fear of complications due to advancing therapy, and deficient knowledge and training regarding how to address these concerns. As mentioned above, patients are often resistant to advancing insulin therapy primarily due to common misconceptions, including: fear and concern about additional injections, the belief that more insulin and/or more injections means that their health is worsening, concern that additional insulin will contribute to poorer health outcomes, feelings of being overwhelmed by the complexity that mealtime therapy will presumably introduce, the possibility of social stigma, and worries about weight gain and hypoglycemia.

 

Acknowledgment of Commercial Support

  • This activity is supported by an educational grant from Sanofi US.
 
 
 
 
Message
OK